Caris Life Sciences, Inc. Common Stock (CAI)vsBeiGene, Ltd. (ONC)
CAI
Caris Life Sciences, Inc. Common Stock
$18.56
-3.53%
HEALTHCARE · Cap: $5.44B
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 558% more annual revenue ($5.34B vs $812.03M). ONC leads profitability with a 5.4% profit margin vs -8.4%. ONC earns a higher WallStSmart Score of 42/100 (D).
CAI
Hold41
out of 100
Grade: D
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CAI.
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 30.2%
Revenue surging 125.4% year-over-year
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Trading at 9.1x book value
0.0% earnings growth
ROE of -45.4% — below average capital efficiency
Distress zone — elevated risk
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : CAI
The strongest argument for CAI centers on Operating Margin, Revenue Growth. Revenue growth of 125.4% demonstrates continued momentum.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : CAI
The primary concerns for CAI are Price/Book, EPS Growth, Return on Equity.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Key Dynamics to Monitor
CAI is growing revenue faster at 125.4% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ONC scores higher overall (42/100 vs 41/100) and 32.8% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Caris Life Sciences, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
CAI International, Inc. is a transportation finance company in the United States, Switzerland, France, Korea, Singapore, Rest of Asia, Rest of Europe, and internationally. The company is headquartered in San Francisco, California.
Visit Website →BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?